Brickell Biotech, Inc. (NASDAQ:BBI) traded down 12.9% on Tuesday . The company traded as low as $1.11 and last traded at $1.21. 3,808,690 shares were traded during trading, a decline of 26% from the average session volume of 5,172,037 shares. The stock had previously closed at $1.39.
Separately, Zacks Investment Research downgraded Brickell Biotech from a “buy” rating to a “hold” rating in a report on Wednesday, January 6th.
The company has a market capitalization of $64.75 million, a P/E ratio of -0.50 and a beta of 0.34. The company has a 50 day moving average of $1.25 and a 200-day moving average of $0.88.
About Brickell Biotech (NASDAQ:BBI)
Brickell Biotech, Inc, a clinical-stage pharmaceutical company, focuses on identifying, developing, and commercializing various prescription therapeutics for the treatment of debilitating skin diseases in the United States. The company's lead product candidate is sofpironium bromide that is in phase 3 clinical trial to treat patients with primary axillary hyperhidrosis.
Further Reading: What is the S&P/ASX 200 Index?
Receive News & Ratings for Brickell Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Brickell Biotech and related companies with MarketBeat.com's FREE daily email newsletter.